ARTICLE | Emerging Company Profile

Abdera: optimizing tunable radiotherapeutics for safety

Backed with $142M, start-up aims to thread a PK needle for antibody-based radiotherapies, avoiding kidney and bone marrow issues

April 20, 2023 10:34 AM UTC

Abdera believes its approach to creating tunable radiotherapeutics will allow it to reach a broader range of targets than others can address while avoiding the main types of toxicity associated with the modality.

Emerging from stealth mode on Thursday with $142 million across two rounds of funding, Abdera Therapeutics Inc. is developing a lead program targeting DLL3 built from its Radio Optimized Vector Engineering (ROVEr) platform, which includes custom-built antibodies with engineered Fc domains for optimized pharmacokinetics...